Please login to the form below

Not currently logged in
Email:
Password:

Flynn Pharma

This page shows the latest Flynn Pharma news and features for those working in and with pharma, biotech and healthcare.

Pfizer, Flynn face reinstatement of £90m CMA fine

Pfizer, Flynn face reinstatement of £90m CMA fine

Facing penalty for dramatic price hikes of an epilepsy drug. The UK’s competition regulator is pushing to reinstate a £90m fine for Pfizer and Flynn Pharma – quashed last year – over ... 2016 and set damages of £84.2m for Pfizer and £5.2m for

Latest news

  • Concordia accused of overcharging NHS for thyroid drug Concordia accused of overcharging NHS for thyroid drug

    The pharma firm said to have ‘abused’ its position within the UK market. ... Last December, Pfizer and Flynn Pharma were ordered to pay £84m after being accused of charging excessive and unfair prices for anti-epilepsy treatment phenytoin sodium

  • MSD probed by UK for blocking Remicade biosimilars MSD probed by UK for blocking Remicade biosimilars

    The action is the latest in a series launched by the CMA into the pharma industry. ... Last year it fined Pfizer £84m for conspiring with Flynn Pharma to raise the price of epilepsy drug phenytoin, and has since launched an investigation into the

  • EU starts investigation of Aspen's cancer drug pricing EU starts investigation of Aspen's cancer drug pricing

    The European Commission said it was looking into concerns that the South African pharma company had "engaged in excessive pricing" for the five drugs - with reports that some drugs had their ... Last December, Pfizer was fined £84m by the Competitions

  • Pfizer gets record £84m fine for hiking price of epilepsy drug Pfizer gets record £84m fine for hiking price of epilepsy drug

    The Competition and Markets Authority (CMA) has levied an £84.2m fine on Pfizer - as well as a £5.2m penalty for distributor Flynn Pharma - saying they hiked the price of ... increase for toxoplasmosis drug Daraprim (pyrimethamine) prompted a public

  • Pfizer and Flynn accused of overcharging for epilepsy drug Pfizer and Flynn accused of overcharging for epilepsy drug

    Pfizer and Flynn Pharma are under investigation amid claims they charged "excessive and unfair" prices for a widely-used epilepsy drug in the UK. ... the UK distribution rights to Flynn Pharma in 2012, which promptly de-branded the product.

More from news
Approximately 0 fully matching, plus 7 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Spirit, an OPEN Health Company

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....